Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial

By sjmartinez • November 15, 2023

Ji J, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O'Connor T, Moy B, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Gross CP, Cohen HJ, Muss HB, Sedrak MS. Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial. Cancer. 2023 Nov 14. doi: 10.1002/cncr.35105. Epub ahead of print. PMID: 37962093.

Tags: adjuvant chemotherapy, breast cancer, Falls, geriatric assessment, Hematology/Oncology, Hospitalization, Older adults, Publications, toxicity

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]

Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]

Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology

Yang H, Ribas A. Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology. J Thorac Oncol. 2025 Nov;20(11):1565-1568. doi: 10.1016/j.jtho.2025.08.009. PMID: 41203378.